More about

Nivolumab

News
September 24, 2021
2 min read
Save

Nivolumab plus rucaparib shows ‘noteworthy activity’ in subset of men with prostate cancer

Nivolumab plus rucaparib shows ‘noteworthy activity’ in subset of men with prostate cancer

Nivolumab plus rucaparib demonstrated activity among men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of cohort A2 of the CheckMate 9KD trial presented during the virtual ESMO Congress 2021.

News
September 20, 2021
1 min read
Save

FDA grants priority review to relatlimab-nivolumab regimen for advanced melanoma

FDA grants priority review to relatlimab-nivolumab regimen for advanced melanoma

The FDA granted priority review to relatlimab and nivolumab for treatment of unresectable or metastatic melanoma.

News
September 17, 2021
3 min read
Save

Immunotherapy combination maintains OS advantage in malignant pleural mesothelioma

Immunotherapy combination maintains OS advantage in malignant pleural mesothelioma

The combination of nivolumab and ipilimumab maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results.

News
September 17, 2021
3 min read
Save

Nivolumab-ipilimumab combination confers durable benefit in advanced renal cell carcinoma

Nivolumab-ipilimumab combination confers durable benefit in advanced renal cell carcinoma

First-line nivolumab plus ipilimumab conferred durable survival benefit compared with sunitinib for patients with advanced renal cell carcinoma, according to results of the randomized phase 3 CheckMate-214 trial.

News
September 13, 2021
1 min read
Save

Nivolumab plus ipilimumab confers sustained OS benefit in malignant pleural mesothelioma

Nivolumab plus ipilimumab confers sustained OS benefit in malignant pleural mesothelioma

Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer.

News
September 09, 2021
2 min read
Save

Addition of nivolumab, ipilimumab to chemotherapy extends OS in NSCLC with brain metastases

Addition of nivolumab, ipilimumab to chemotherapy extends OS in NSCLC with brain metastases

The addition of nivolumab and ipilimumab to first-line chemotherapy conferred durable survival benefits to patients with advanced non-small cell lung cancer and brain metastases, according to results of the phase 3 CheckMate 9LA trial.

News
August 20, 2021
2 min read
Save

FDA approves Opdivo as adjuvant treatment of high-risk urothelial carcinoma

FDA approves Opdivo as adjuvant treatment of high-risk urothelial carcinoma

The FDA approved nivolumab for adjuvant treatment of patients with surgically resected, high-risk urothelial carcinoma, according to the agent’s manufacturer.

News
July 26, 2021
1 min read
Save

Bristol Myers Squibb withdraws liver cancer indication for nivolumab

Bristol Myers Squibb in consultation with the FDA voluntarily withdrew the indication for nivolumab as monotherapy for patients with hepatocellular carcinoma previously treated with sorafenib.

News
July 16, 2021
1 min read
Save

Trial of nivolumab plus ipilimumab for first-line HNSCC misses primary endpoints

Trial of nivolumab plus ipilimumab for first-line HNSCC misses primary endpoints

A phase 3 trial of nivolumab plus ipilimumab vs. the EXTREME regimen as first-line treatment of advanced squamous cell carcinoma of the head and neck failed to meet its primary endpoints of OS, according to a company-issued press release.

News
July 14, 2021
2 min watch
Save

VIDEO: CheckMate 816 trial supports treatment prior to surgery for resectable NSCLC

VIDEO: CheckMate 816 trial supports treatment prior to surgery for resectable NSCLC

In this video, Sonam Puri, MD, discusses the surgical outcomes from the phase 3 CheckMate 816 trial presented at this year’s virtual annual ASCO meeting.

View more